Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT02949128 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Atypical Hemolytic Uremic Syndrome (aHUS)

Interventions

BIOLOGICAL: Ravulizumab

Sponsor

Alexion Pharmaceuticals, Inc.